Abstract:DPAGT1-CDG is a Congenital Disorder of Glycosylation (CDG) that lacks effective therapies. It is caused by mutations in the gene DPAGT1 which encodes the first enzyme in N-linked glycosylation. We used a Drosophila rough eye model of DPAGT1-CDG with an improperly developed, small eye phenotype. We performed a drug repurposing screen on this model using 1,520 small molecules that are 98% FDA/EMA-approved to find drugs that improved its eye. We identified 42 candidate drugs that improved the DPAGT1-CDG model. Notably from this screen, we found that pharmacological and genetic inhibition of the dopamine D2 receptor partially rescued the DPAGT1-CDG model. Loss of both dopamine synthesis and recycling partially rescued the model, suggesting that dopaminergic flux and subsequent binding to D2 receptors is detrimental under DPAGT1 deficiency. This links dopamine signaling to N-glycosylation and represents a new potential therapeutic target for treating DPAGT1-CDG. We also genetically validate other top drug categories including acetylcholine-related drugs, COX inhibitors, and an inhibitor of NKCC1. These drugs and subsequent analyses reveal novel biology in DPAGT1 mechanisms, and they may represent new therapeutic options for DPAGT1-CDG. Some proteins require the attachment of sugars—like mannose and galactose—in order to perform their function. The process that attaches these sugars is called "glycosylation". Genetic mutations in glycosylation pathways cause Congenital Disorders of Glycosylation ("CDGs"). CDGs are devastating disorders causing a multitude of symptoms, including seizures and developmental delay, and they have few treatment options. We wanted to find new potential treatment options for the CDG called DPAGT1-CDG. We use a model of DPAGT1-CDG that has inhibited glycosylation resulting in impaired eye development. We used a "drug repurposing screen", where we screened 1,520 drugs that are 99% FDA- or EMA-approved, to find drugs that improved its eye. We found 42 drug hits, including classes like dopamine receptor inhibitors, NSAIDs, and antihistamines. We found that the dopamine receptor inhibitors caused the strongest improvement. In addition, genetically impairing multiple parts of the dopamine pathway (e.g. how dopamine is made or recycled) also improved the model. This suggests that dopamine signaling is important in DPAGT1-CDG, and it could represent a new therapeutic option for patients. Overall, we present validation of several of our drugs, and these represent potential new treatments while also improving our understanding of glycosylation.

Development of new NGLY1 assay systems - toward developing an early screening method for NGLY1 deficiency

Development of a Fluorescence and Quencher-based FRET Assay for Detection of Endogenous Peptide:N-glycanase/NGLY1 Activity

[Clinical and Genetic Analyses of a Family with Atypical Nonketotic Hyperglycinemia Caused by Compound Heterozygous Mutations in the GLDC Gene].

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

A full spectrum PNGase activity analysis of R328 mutations on NGLY1

Functional Prediction of the Potential NGLY1 Mutations Associated with Rare Disease CDG

Doubling of Optic Disc

Novel NGLY1 gene variants in Chinese children with global developmental delay, microcephaly, hypotonia, hypertransaminasemia, alacrimia, and feeding difficulty

Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency

Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

N-glycanase NGLY1 Regulates Mitochondrial Homeostasis and Inflammation Through NRF1

Comparative proteomics reveals elevated CCN2 in NGLY1-deficient cells

AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia

Structural basis of sugar recognition by SCFFBS2 ubiquitin ligase involved in NGLY1 deficiency

Research Progress of The Peptide??N-Glycanase (PNGase) br

A Novel N-Tetrasaccharide In Patients With Congenital Disorders Of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, And Mannose Phosphate Lsomerase Deficiencies

AB054. Experiences During Newborn Screening for Glutaric Aciduria Type 1: Diagnosis, Treatment, Genotype, Phenotype and Outcomes

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Discovery of Highly Active Recombinant PNGase H+ Variants Through the Rational Exploration of Unstudied Acidobacterial Genomes

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent